Boston, US – At the CAR-TCR Summit Series, Venera Kuci Emruli from Strike Pharma participated in scientific discussions highlighting the rapid progress and evolving landscape within CAR-T and TCR-based therapies.

Key topics addressed throughout the meeting included the growing potential of in-vivo CAR-T approaches, continued expansion of CAR-T therapies beyond oncology indications, and the importance of collaboration across industry and academia to accelerate development and improve patient access. Discussions also focused on advances in manufacturing technologies aimed at reducing production timelines and costs, the role of robust analytical methods in process development and quality assurance, and the potential benefits of introducing CAR-T therapies earlier in treatment pathways. In addition, patient advocacy and patient-centred perspectives were highlighted as important drivers in the continued advancement and accessibility of cell therapies.